麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT MARKETING AUTHORIZATION APPLICATION FOR LECANKITUG INJECTION ACCEPTED FOR REVIEW BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Recently, Livzon MABPharm Inc.*(珠海市麗珠單抗生物技術有限公司) ("**Livzon MAB**"), a controlling subsidiary of Livzon Pharmaceutical Group Inc.*(麗珠醫藥集團股份有限公司) (the "**Company**"), received the Acceptance Notice (Acceptance No.: CXSS2500144) approved and issued by the National Medical Products Administration* (國家藥品監督管理局) ("**NMPA**"). The marketing authorization application for the domestically produced drug, Lecankitug Injection (萊康奇塔單抗注射液) (the "**Drug**") jointly developed by Livzon MAB and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd.*(北京鑫康合生物醫藥科技有限公司), has been accepted by the NMPA. Relevant details are announced as follows:

BASIC INFORMATION OF THE DRUG

Drug name: 萊康奇塔單抗注射液

English/Latin name: Lecankitug Injection

Dosage form: Injection

Specification: 160mg (1.6mL) / vial

Application item: Marketing authorization application for domestically produced drug

Category of registration: Class 1 therapeutic biological product

Applicant: Livzon MABPharm Inc.* (珠海市麗珠單抗生物技術有限公司)

Proposed indication (or main treatments): The Drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Approval conclusion of the Acceptance Notice: In accordance with the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China* (《中華人民共和國行政許可法》), after review, it is decided to accept the application.

DRUG R&D AND RELEVANT INFORMATION

Psoriasis is a chronic inflammatory skin disease induced by a combination of genetic, immune, and environmental factors, affecting approximately 100 million patients globally. Lecankitug Injection, as the first domestically developed and the second globally developed innovative dual IL-17A/F inhibitor, exerts its effect by simultaneously blocking the pro-inflammatory factors IL-17A and IL-17F. In July 2025, the multicentre, randomized, double-blind, active-controlled (vs. secukinumab) clinical trial of the Drug in patients with moderate-to-severe plaque psoriasis met both the primary and secondary efficacy endpoints. Study results showed that compared to the control group (secukinumab), the Drug demonstrated superior PASI 100 response rate at week 12, PASI 75 response rate at week 4, and PASI 100 response rate at week 52, reflecting its characteristics of rapid onset, excellent short-term efficacy, long-lasting durability, and lower dosing frequency. The Drug demonstrated a favorable safety profile, with the incidence of common adverse events comparable to that of various adverse events in the control group. For specific details regarding the clinical trial of the Drug, please refer to the Company's Voluntary Announcement on Achievement of The Primary Endpoint in Phase III Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection disclosed on 21 July 2025.

The Drug is jointly developed by Livzon MAB and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd.* (北京鑫康合生物醫藥科技有限公司).

As at the date of this announcement, the cumulative direct investment in research and development expenses for Lecankitug Injection amounts to approximately RMB 204.03 million (unaudited).

MARKET CONDITION OF THE DRUG

According to information from the NMPA and the Center for Drug Evaluation ("**CDE**") website databases, as at the date of this announcement, no product targeting IL-17A/F has been approved for marketing in China for the psoriasis indication. Regarding single-target products against IL-17A and IL-17RA, a total of three imported products and two domestically produced products have been approved for marketing in China.

Based on IQVIA sampling estimation data, the domestic terminal sales value for single-target IL-17A and IL-17RA drugs in 2024 was RMB 2.833 billion.

RISK WARNING

In accordance with the relevant national laws and regulations on drug registration, the marketing authorization application for Lecankitug Injection, upon acceptance by the NMPA, will proceed to the review and approval process by the CDE. The time for completion and the approval result are subject to uncertainty. The Company will timely fulfill its information disclosure obligations in accordance with the progress of the registration application. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
24 December 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director of the Company is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

* *For identification purpose only*